Background: While severe outcomes among hospitalised patients with COVID-19 and influenza are well described, comparative studies on community transmission and milder illnesses associated with COVID-19 and influenza are lacking.
Methods: We compared incidence, risk/protective factors, and clinical features among prospective community cohort participants with PCR-confirmed COVID-19-associated and influenza-associated acute respiratory illnesses (ARI) from 7-February to 2-October 2022 in Wellington, New Zealand.
Findings: The crude COVID-19-associated ARI incidence was 59/100 person-years (PY). The adjusted cumulative incidence for COVID-19 [77/100-PY;95%CI,75-80] was 4.5 times higher than for influenza [17/100-PY;95%CI,15-19]. The proportion of children (0-17 years) with COVID-19 of all COVID-19 cases was substantial but smaller than those of influenza [402/1229 (33%) vs 173/255 (68%), p<0.0001]. The highest incidence of COVID-19 was among adolescents (12-17 years) [109/100-PY;95%CI,97-119] and non-Māori/Pacific [83/100-PY;95%CI,80-86] whereas the highest influenza incidence was among children (1-4 years) [49/100-PY;95%CI,40-58] and Māori [35/100-PY;95%CI,28-43].Adolescents (12-17 years) had 2.5 times higher peak COVID-19 incidence (5.9/100) than adults ≥18 years (2.4/100). Adolescents with two doses of the COVID-19 vaccines had 75% greater risk of COVID-19 infection [hazard ratio:1.75,95%CI,1.40-2.20] compared to adults with three doses.Vaccination, age, ethnicity, and household size were independent protective/risk factors for COVID-19 or influenza.Participants with COVID-19, compared with influenza, were less likely to access healthcare or experience febrile/severe illnesses, but more likely to report sore throat, headache, myalgia, and taste/smell loss.
Interpretation: As the world transitions to COVID-19 endemicity, estimating disease burdens in community settings becomes important to understand complete disease pyramids, risk factors and clinical progression for informing countermeasures.
Keywords: COVID-19 or SARS-CoV-2; acute respiratory illnesses; clinical features; influenza; prospective community cohort; risk factor.
© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.